Fecal Calprotectin Levels in Mycophenolate Mofetil Induced Diarrhea and Treatment With Octreotide

University Health Network, Toronto10 enrolled

Overview

Prospective, observational pilot study of ten post-transplant patients presenting with diarrhea while taking Mycophenolate Mofetil (MMF). These patients will undergo a standard workup to confirm MMF induced diarrhea. A stool fecal calprotectin will be measured to determine if it may be helpful in confirming the diagnosis of MMF associated diarrhea. Once the diagnosis is confirmed, the patients will then be treated with a short course of subcutaneous Octreotide which has been shown to cure this type of diarrhea.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Diarrhea Immunosuppression

Interventions

Octreotide AcetateDRUG

Octreotide 100mcg SC q12h for 5 days

Eligibility

Medical Language ↔ Plain English

Inclusion Criteria: * Male and female patients between the ages of 18 and 75 years old who are solid organ transplant recipients followed at Toronto General Hospital on MMF referred to gastroenterology for diarrhea. Exclusion Criteria: 1. Subjects with a known history of IBD or GVHD of the bowel. 2. Any subject receiving Octreotide for another indication. 3. Any patient unable to undergo endoscopy. 4. Any patient with a contraindication to Octreotide therapy.

Outcomes

Primary Outcomes

Measurement of Fecal Calprotectin levels patients with diarrhea on MMF

Time frame: 3 months

Secondary Outcomes

Treatment of patients with MMF induced diarrhea with Octreotide

Time frame: 5 days